Mitochondrial respiratory capacity modulates LPS-induced inflammatory signatures in human blood
All treatment decisions are based on the providers professional medical judgment
For daily GLP-1 medications, taking them in the evening might help you sleep through peak nausea periods, though this effect may be limited for weekly injections due to their long half-life
Market Players, Key Developments, and Competitive Intelligence To learn more about this report, Key Developments On June 30, 2025, Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on peptide-based therapeutics, announced the nomination of PN-477, a triple agonist peptide targeting GLP-1, GIP, and GCG receptors, for obesity treatment